Results 181 to 190 of about 29,271 (207)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL [PDF]
New England Journal of Medicine, 2018 Jennifer A Woyach +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [PDF]
New England Journal of Medicine, 2015 Jan A Burger +2 more
exaly +2 more sources
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2023Jennifer R Brown +2 more
exaly
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Circulation, 2020Ling Xiao +2 more
exaly